The Bleeding Time

Lind, Stuart E.; Kurkjian, Carla

doi:10.1016/b978-012369367-9/50787-4

Cited by 12 publications

(36 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No single test of platelet function can capture all of these distinct yet integrated biological events. The bleeding time might be considered a test of platelet aggregate formation and primary hemostasis, but this test varies greatly among individuals, is not specific or sensitive for drug-or disease-related effects, and is highly subject to technical and operator influences (53). Choice of anticoagulant.…”

Section: Pitfalls In Monitoring Platelet Functionmentioning

confidence: 99%

Platelet Function Monitoring in Patients With Coronary Artery Disease

Gurbel

Becker

Mann

et al. 2007

Journal of the American College of Cardiology

435

335

View full text Add to dashboard Cite

Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and clopidogrel, have increased in recent years. However, the relations of in vivo platelet function and adverse clinical events to results of ex vivo platelet function tests remain largely unknown. This article describes current methods of measuring platelet function in various clinical and research situations and their advantages and disadvantages, reviews evidence for antiplatelet response variability and resistance, discusses the potential pitfalls of monitoring platelet function, and demonstrates emerging data supporting the positive clinical and treatment implications of platelet function testing.

show abstract

Section: Pitfalls In Monitoring Platelet Functionmentioning

confidence: 99%

Platelet Function Monitoring in Patients With Coronary Artery Disease

Gurbel

Becker

Mann

et al. 2007

Journal of the American College of Cardiology

435

335

View full text Add to dashboard Cite

show abstract

“…Closure time (CT), measured by platelet function analyzer (PFA‐100 ® ) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleeding time [1–4]. On behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH‐SSC), this document reviews recent literature and provides consensus recommendations on using PFA‐100 CT in the evaluation of platelet function within the clinical laboratory.…”

Section: Introductionmentioning

confidence: 99%

Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function

Hayward

Harrison

Cattaneo

et al. 2006

Journal of Thrombosis and Haemostasis

363

274

View full text Add to dashboard Cite

Summary. Background: Closure time (CT), measured by platelet function analyzer (PFA‐100®) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleeding time test. Aim: On behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH‐SSC), a working Group was formed to review and make recommendations on the use of the PFA‐100 CT in the evaluation of platelet function within the clinical laboratory. Methods: The Medline database was searched to review the published information on the PFA‐100 CT in the evaluation of platelet disorders and platelet function. This information, and expert opinion, was used to prepare a report and generate consensus recommendations. Results: Although the PFA‐100 CT is abnormal in some forms of platelet disorders, the test does not have sufficient sensitivity or specificity to be used as a screening tool for platelet disorders. A role of the PFA‐100 CT in therapeutic monitoring of platelet function remains to be established. Conclusions: The PFA‐100 closure time should be considered optional in the evaluation of platelet disorders and function, and its use in therapeutic monitoring of platelet function is currently best restricted to research studies and prospective clinical trials.

show abstract

“…Aspirin ® and other non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the metabolism of arachidonic acid through the inactivation of the cyclooxygenase enzyme (COX) [43,95,101] (Figure 4). …”

Section: Arterial Thrombosis X Treatmentmentioning

confidence: 99%

“…However, in cases of patients with the estimated risk of a cardiovascular event higher than 1% per year, the therapy with aspirin ® for cardiovascular protection is highly indicated [43,103,108] (Figure 4). …”

Section: Arterial Thrombosis X Treatmentmentioning

confidence: 99%